# OnCo record ielsg43 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ielsg43/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ielsg43", "NCT02531841" ;
  schema:name "MATRix/IELSG43"@en ;
  schema:alternateName "IELSG43"@en, "IELSG-43"@en, "MATRix"@en ;
  schema:description "MATRix/IELSG43 settled how to consolidate remission in lymphoma of the brain: after MATRix chemotherapy, a high-dose chemotherapy and stem cell transplant kept 78 percent of patients free of progression at three years against 51 percent with conventional consolidation chemotherapy, and also lengthened survival, so transplant is now the preferred consolidation for fit patients."@en ;
  schema:url <https://onco.cc/trials/ielsg43/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02531841> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/primary-cns-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/brain-tumours/> ;
  onco:technologies <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/thiotepa/>, <https://onco.cc/drugs/carmustine/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:institutions <https://onco.cc/institutions/ccc-freiburg/>, <https://onco.cc/institutions/ielsg/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-matrix-ielsg43-asct-consolidation-pcnsl-illerhaus-lancet-2026/> .